Breast Cancer Updates and T-Cell Stemness

This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial. And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion:…